BIGBEAR
PHARMACEUTICALS
Acalabrutinib is a prescription medication indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
AuthenticGuaranteeFast DeliveryPrivacy October 31, 2017 -- The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults ···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 70
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patien···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 71
17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatmen···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 71
Key Advantages of the New Tablet Formulation- New formulation can be co-administered with gastric acid-reducing agents- Tablet offers equivalent effic···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 71
20 February 2026 -- AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-du···【Read More】
Update: 26 Feb,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
